8 (tied). ImmusanT
Venture capital raised: $40 million
ImmusanT raised $40 million in venture capital during its expansion stage of development in the fourth quarter of 2017, according to the MoneyTree Report. This is the company’s third investment sequence and investors include ARCH Venture Partners and Vatera Healthcare Partners.
ImmusanT is working to increase tolerance to gluten in people who have celiac disease. The company is improving diagnosis and treatment by harnessing new discoveries in immunology. ImmusanT is developing a therapeutic vaccine for celiac disease called Nexvax2, as well as a diagnostic and monitoring tool to improve management of the disease.